Pentavalent Market Report 2025

The pentavalent market size has grown steadily in recent years. It will grow from $2.62 billion in 2024 to $2.73 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to global immunization initiatives, government vaccination programs, prevention of multiple diseases, public health awareness, international partnerships and funding.

The pentavalent market size is expected to see steady growth in the next few years. It will grow to $3.31 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to continued global immunization efforts, expansion of vaccination programs, introduction in new geographies, research and development initiatives, collaborations for vaccine access. Major trends in the forecast period include global health initiatives and funding support, public awareness and education campaigns, government policies and regulatory frameworks, technological innovations in vaccine manufacturing.

The pentavalent market is poised for growth, driven by the increasing prevalence of diphtheria. Corynebacterium diphtheriae, a bacterium causing the highly contagious and severe disease diphtheria, poses significant health challenges, including difficulties with eating, breathing, and the potential development of skin ulcers. The pentavalent vaccine offers protection against Diphtheria diseases through a 3-dose schedule of pentavalent immunization for children. This rise in the prevalence of diphtheria has led to an increased demand for pentavalent vaccines. A noteworthy example is the data reported by the World Health Organization in 2022, highlighting an unusually high number of diphtheria cases recorded through the International Health Regulations reporting process. Seven nations reported 144 instances of diphtheria, with a significant impact on asylum seekers. Clinically compatible cases constituted 69%, toxigenic diphtheria cases confirmed by laboratory testing were 31%, and 2% were suspected cases. Consequently, the escalating prevalence of diphtheria is a driving force behind the growth of the pentavalent market.

The pentavalent market is expected to experience growth, propelled by the increasing healthcare expenditure. Healthcare expenditure encompasses the total resources, both monetary and other, allocated for the provision of healthcare services within a specific timeframe. In the context of pentavalent vaccines, healthcare expenditure involves financial resources dedicated to the development, production, distribution, and administration of vaccines targeting five different diseases. In December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported a 4.1 percent increase in healthcare expenditures in the United States in 2022, reaching a total of $4.5 trillion, equivalent to $13,493 per individual. This substantial rise in healthcare expenditure is a key factor driving the growth of the pentavalent market.

Product innovation has become a prominent and widely adopted trend in the pentavalent market, with major companies actively focusing on the development of innovative products to strengthen their market positions. An illustrative example is Pfizer, a US-based pharmaceutical company operating in the pentavalent vaccines market. In December 2022, Pfizer secured approval from The United States Food and Drug Administration (FDA), a federal agency of the Department of Health and Human Services, for its Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents. This vaccine is designed to prevent meningococcal disease in individuals aged 10 to 25. The unique aspect of the MenABCWY vaccine lies in its combination of components from two vaccines into one, providing protection against the meningococcal serogroups that are responsible for the majority of invasive meningococcal diseases. This strategic product innovation reflects a commitment to addressing public health needs and advancing the effectiveness of vaccines in preventing serious illnesses.

Major companies in the pentavalent market are actively focused on developing innovative solutions, particularly in the realm of pentavalent immunization vaccines. These vaccines represent a combination designed to protect against five different diseases. A notable example is Pfizer, a US-based pharmaceutical company, which in October 2023, announced FDA approval for its 'Penbraya' pentavalent vaccine. This groundbreaking vaccine is the first and only one providing protection against the five most prevalent meningococcal serogroups - A, B, C, W-135, and Y - in individuals aged 10 through 25 years. The Penbraya vaccine incorporates elements from the Trumenba meningococcal group B vaccine and the Nimenrix meningococcal groups A, C, W-135, and Y conjugate vaccine. It has been identified as effective in offering protection against the five meningococcal serogroups responsible for the majority of global cases of invasive meningococcal disease. This signifies a strategic move towards advancing comprehensive immunization solutions to address significant public health concerns.

In January 2022, Ardian, a private equity investment firm headquartered in France, successfully completed the acquisition of Biofarma Group for an undisclosed sum. This strategic transaction positions Ardian to facilitate increased consolidation and international expansion within the market. Biofarma Group, an Italy-based entity specializing in the pentavalent vaccines market, now stands as a key asset within Ardian's portfolio, contributing to the company's broader strategic goals and market positioning.

Major companies operating in the pentavalent market include Pfizer Inc., Merck & Co Inc., Sanofi SA, GlaxoSmithKline plc, Shandong Xinhua Pharmaceutical Company Limited, PT Bio Farma (Persero), Shantha Biotechnics Limited, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co Ltd., Changchun Changsheng Biotechnology Co Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, PanGen Biotech Inc., Bharat Biotech International Limited, Vacsera Ltd., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co Ltd.

Asia-Pacific was the largest region in the pentavalent market in 2024. The regions covered in the pentavalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pentavalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pentavalent refers to a vaccine that safeguards children against five life-threatening diseases. Among these diseases, it includes protection against rotavirus infection, which can cause symptoms such as fever, vomiting, and diarrhea in infants and young children.

The primary types of pentavalent vaccines include sodium stibogluconate and meglumine antimoniate. Lyophilization, a method of removing water, is commonly employed to preserve perishable products, extend shelf life, or facilitate easier transportation. Formulation types encompass lyophilized and liquid variations, serving diverse applications in hospitals, pharmacies (both retail and online), and healthcare settings.

The pentavalent market research report is one of a series of new reports that provides pentavalent market statistics, including pentavalent industry global market size, regional shares, competitors with a pentavalent market share, detailed pentavalent market segments, market trends and opportunities, and any further data you may need to thrive in the pentavalent industry. This pentavalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pentavalent market consists of sales of pentavalent vaccines such as those for diphtheria, pertussis, tetanus, hepatitis B, and Hib that treat a child against potentially fatal diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.